First and Second-Line Anti-Tuberculosis Drug-Resistance Patterns in Pulmonary Tuberculosis Patients in Zambia
-
Published:2023-01-12
Issue:1
Volume:12
Page:166
-
ISSN:2079-6382
-
Container-title:Antibiotics
-
language:en
-
Short-container-title:Antibiotics
Author:
Monde Ngula, Munyeme MussoORCID, Chongwe GershomORCID, Wensman Jonas Johansson, Zulu MildredORCID, Siziya SeterORCID, Tembo Rabecca, Siame Kabengele K., Shambaba Obi, Malama Sydney
Abstract
Background: Drug-resistant tuberculosis has continued to be a serious global health threat defined by complexity as well as higher morbidity and mortality wherever it occurs, Zambia included. However, the paucity of information on drug-susceptibility patterns of both first-line and second-line anti-tuberculosis (anti-TB) drugs, including the new and repurposed drugs used in the management of drug-resistant tuberculosis in Zambia, was the major thrust for conducting this study. Methods: A total of 132 bacteriologically confirmed TB isolates were collected from patients with pulmonary TB during the period from April 2020 to December 2021 in Southern and Eastern Provinces of Zambia. Drug-resistance profiles were determined according to four first-line and five second-line anti-TB drugs. Standard mycobacteriological methods were used to isolate and determine phenotypic drug susceptibility. Data on the participants’ social–demographic characteristics were obtained using a pre-test checklist. Results: Overall, the prevalence of resistance to one or more anti-TB drugs was 23.5% (31/132, 95% CI: 16.5–31.6%). A total of 9.8% (13/132, 95% CI: 5.3–16.2%) of the patients had multidrug-resistant TB and 1.2% were new cases, while 25.5% had a history of being previously treated for TB. Among those with mono-resistant TB strains, isoniazid (INH) resistance was the highest at 9.8% (13/132, 95% CI: 5.3–16.2%). Two (2/31) (6.5%) XDR-TB and one (1/31) (3.2%) pre-XDR-TB cases were identified among the MDR-TB patients. Previously treated patients were 40 times more likely (OR; 40.3, 95% CI: 11.1–146.5%) to have drug-resistant TB than those who had no history of being treated for TB. Conclusion: This study has established a high rate of multidrug-resistant TB and has further identified both pre-XDR- and XDR-TB. There is a need to intensify surveillance of MDR- and XDR-TB to inform future guidelines for effective treatment and monitoring.
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology
Reference81 articles.
1. Drug-resistant tuberculosis and hiv infection: Current perspectives;Singh;HIV/AIDS-Res. Palliat. Care,2020 2. World Health Organization (2018). Technical Manual for Drug Susceptibility Testing of Medicines Used in the Treatment of Tuberculosis, World Health Organization. Available online: https://apps.who.int/iris/handle/10665/275469. 3. Treatment outcomes of patients with multidrug and extensively drug-resistant tuberculosis in Zhejiang, China;Zhang;Eur. J. Med. Res.,2021 4. Bhering, M., Duarte, R., and Kritski, A. (2019). Predictive factors for unfavourable treatment in MDR-TB and XDR-TB patients in Rio de Janeiro State, Brazil, 2000–2016. PLoS ONE, 14. 5. Alene, K.A., Yi, H., Viney, K., McBryde, E.S., Yang, K., Bai, L., Gray, D.J., Clements, A.C.A., and Xu, Z. (2017). Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China. BMC Infect. Dis., 17.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|